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This paper focuses on the current best-evidence-based clinical practices and controversies surrounding folic acid supplemen-
tation/fortiﬁcation for the prevention of neural tube defects (NTDs) during early pregnancy. The paper also discusses the
controversies surrounding the eﬀect of folic acid on the prevention as well as the promotion of cancer. Suﬃcient data is available
to safelyconclude that folic acid reduces the risk of NTDs during pregnancy; however, a safedosagehas not yet been calculated for
the rest of the population. More research is necessary to study the complete role of folic acid in human growth and development.
1.Folic AcidSupplementationToday
Neural tube defects (NTDs) are common and devastating
congenital malformations of the central nervous system.
Over 90% of the cases are comprised of anencephaly (a total
or partial absence of brain tissue, skull, and overlying skin)
and spina biﬁda (herniation of the spinal cord, meninges,
or both through a defect in the spinal column). Both
arise from incomplete closure of the neural tube early in
gestation, before 28 days after conception, and often before
a woman is aware that she might be pregnant [1]. NTDs are
a worldwide problem, with approximately 300,000 aﬀected
newborns every year and 3,000 cases per year in the United
States alone [2]. A 2005 report from the Centers for Disease
Control (CDC) estimated that the rates for spina biﬁda
and anencephaly were 17.96 and 11.11 per 100,000 live
births, respectively, in the United States [3]. In 1992, the
FDA recommended that every woman of childbearing age
should consume 0.4mg folic acid daily [4]. This 0.4mg
dose was based on several case control and cohort studies
as well as a 1992 Hungarian randomized controlled trial
(RCT) that used 0.8mg daily for primary prevention [5]. In
1999, Berry et al. provided additional evidence for 0.4mg
supplementation when a study carried out in China showed
signiﬁcant primary preventionofNTDswiththatdose[6,7].
The protective eﬀect of folic acid delivered during the
periconceptual period is the best studied of the numer-
ous potential environmental factors contributing to NTDs.
Folate is a water-soluble B vitamin that acts as a cofactor
in one-carbon transfer reactions and plays a central role in
nucleic acid biosynthesis [8]. Emerging research shows that
folic acid may play dual and opposite roles in relation to
cancer promotion [9–11]. Because folate deﬁciency has long
been suspected to promote cancer through destabilization of
the genome, possibly through increased homocysteine levels,
decreased methylation of the genome, uracil misincorpo-
ration, and double-strand breaks of DNA leading to chro-
mosomal damage [12, 13], adequate levels of folate could
be protective against carcinogenesis through stabilization of
the genome. However, because of the critical role that folate
plays in nucleic acid biosynthesis, it may also have a role
in cancer promotion in susceptible individuals. In patients
harboring preneoplastic and neoplastic lesions, exposure
to extra folate (through supplementation or fortiﬁcation)
could potentially promote cellular proliferation and cancer
growth[10,14].Thisisparticularly trueforthoseindividuals2 International Journal of Family Medicine
who already possess tissues which have undergone early
changes characteristic of malignancy. For example, in a
standard chemical carcinogen rodent model of colorectal
cancer, extreme dosages of folic acid (>20-times the basal
daily dietary requirement) have been shown to increase
the development and progression of colorectal cancer. On
the other hand, two other rodent models have shown that
modest levels of folic acid supplementation (4–10-times the
basal daily dietary requirement)suppressed the development
and progression of colorectal cancer. Both, animal studies
and recent epidemiological studies have begun to challenge
the widely accepted notion that folate status is inversely
related to the risk of developing cancers [14]. Studies have
shown conﬂicting or equivocal results for the role of folic
acid in other cancers, includingbreast [15, 16], prostate[17],
and neuroblastoma cancers [18]. The inability to reach a
consensus represents a pressing issue that deserves further
and detailed study in view of the fortiﬁcation programs that
are underway throughout the world, potentially exposing
billions of people to higher levels of folic acid.
The biochemical pathway of folic acid that works to
prevent NTDs is currently unclear, and many questions
about the processes underlying normal and abnormal neu-
rulation remain unanswered and the subject of continued
investigation [17]. What is well established, however, is that
maternal folic acid intake during the periconceptual period
is eﬀectivein reducing the occurrence of NTDs[19–21]. One
of the most impressive studies illustrating this point was
undertaken in China in an area of high NTD prevalence.
Half the population (geographically conﬁned) was given
folic acid supplementation whereas the other half received
normal prenatal care. Those mothers who had received
supplementation had signiﬁcantly fewer infants with NTDs
[6].
2.Controversiesin Practice
Unfortunately, putting prevention into practice has been
more diﬃcult than initially anticipated, and numerous
controversies are present throughout the literature about
some of the most important folic acid-related issues facing
women and public health authorities worldwide. Among the
contentious issues are questions related to the optimal dose
of supplemental folic acid (for the prevention of NTDs),
the safety of folic acid among individuals of all ages, the
risk beneﬁt proﬁles of synthetic and naturally derived folic
acid, the optimal level of fortiﬁcation, and if this is even an
eﬀective strategy, and the root causes of NTDs in diﬀerent
populations. For example, a study on racial and ethnic
diﬀerences in NTD rates showed that Hispanics had the
highest rates of NTD-aﬀected pregnancies, non-Hispanic
blacks and Asians the lowest, and the rates of non-Hispanic
whites being intermediate between the two [22]. The reason
for such disparities is unclear, and the involved factors
likely go far beyond inherent folic acid status in diﬀerent
racial/ethnic groups.
The recommended daily allowance of folic acid has been
diﬃcult to assess and remains the subject of much debate.
Although many countries have similar recommendations,
no international consensus is available on dosage, and some
countries do not have oﬃcial recommendations. In 1992,the
United States Food and Drug Administration (FDA) recom-
mended that every woman capable of becoming pregnant
should consume 0.4mg folic acid daily for the prevention of
NTDs [4]. Four years later this same governmental agency
advised folic acid fortiﬁcation of enriched grains, such as
ﬂour, bread, farina, cornmeal, rice, and pastas [23]. Similar
programs were rapidly adopted in many other countries.
Despite these advances in fortiﬁcation, approximately 150
countries, including those of the European Union, have
no requirement for fortiﬁcation, mostly because of safety
concerns [24]. Further studies are needed to evaluate the
safety of high-dose folic acid in certain populations.
3. Folates and Food
The fundamental diﬀerencebetweennaturalfood folatesand
synthetic folic acid is considerable and largely unappreciated
by the medical community and the patients that they treat.
Natural food folates are approximately 50% less bioavailable
than is the synthetic folic acid used in supplements and
fortiﬁcation. This decreased bioavailability is a result of
several factors: (1) the nature of the food matrix, with
some folates remaining bound and unavailable within plant
material; (2) factors aﬀecting the deconjugation of the
polyglutamate form of folates into the monoglutamyl form,
which is the form needed for absorption in the small
intestine; (3) losses incurred during harvesting, processing,
and cooking of foods. Good sources of folate that are often
cited include legumes, orange juice, leafy green vegetables,
broccoli, and whole grains. Whereas synthetic folic acid is
highly stable, leafy green vegetables and legumes undergo a
loss of 50–89% of folate after cooking. For example, broccoli
has diﬀerentfolate valuesdepending on whether it iscooked,
raw, or frozen. The usual Western diet contains about 0.2mg
natural folate per day. Under these circumstances, the 1992
CDC guideline recommending 0.4mg per day of folic acid
means that a woman would have to consume 1000µ/day of
natural food folates to obtain that level, taking into account
the bioavailability diﬀerence [25]. Such a consumption
level is unpractical and underscores the potential value of
population wide supplementation programs. It is axiomatic
that such problems would not be conﬁned solely to women,
and that men would ﬁnd similar diﬃculties if they tried to
rely on diet alone for their daily values.
4.Folic Acidand the QuestionofMalignancy
Suﬃcient data now exists to suggest that a correlation may
be present between the amount of folic acid intake and
between the promotion of cancer. Recent evidence indicates
that folic acid may facilitate the preliminary stages of speciﬁc
types of malignancy. Two Norwegian studies, namely, the
Norwegian VitaminTrialand theWesternNorwayBVitamin
Intervention Trial, found that daily supplementation with
0.8mg of folic acid and 0.4mg B12 for more than three years
increased the risk of lung cancer by 21%. The two studies
measured cancer incidence, cancer mortality, and all-causeInternational Journal of Family Medicine 3
Table 1: Advantages and Disadvantages of Folic Acid Supplementation.
Advantages Disadvantages
When taken before and during pregnancy, reduces numbers
of neural tube defects in newborns [6, 7]
Possible increased risk of lung cancer among smokers with
high dose folic acid intake [26]
When taken during pregnancy, reduces number of heart
defects in newborns, especially ventricular-septal and
conotruncal defects [20]
Increased risk of colorectal cancer, and other cancers with
high dose folic acid [14]
When taken by “subfertile men,” increases spermatic
parameters of absolute numbers and percent motility, while
decreasing the percentage of abnormal forms [28]
Adapted from: [29].
mortality in a total of 6837 patients with ischemic heart
disease. The results were able to show that treatment with
folic acid plus vitamin B12 was associated with increased
cancer outcomes and all-cause mortality in patients with
ischemic heart disease in Norway, where there is no folic acid
fortiﬁcation of foods. Such studies suggest that high dose
folicacidsupplementationmayunexpectedly increasecancer
risks [26]. However, it is important to note that the dose
used in these two trials is twice that recommended on an
international basis for pregnancy-related intakes. Systematic
studies of the safety of high doses of folic acid are lacking,
andthe absenceofdatadoes notimplyassurance ofsafety. At
the same time, observational epidemiologic studies show an
inverse relationship between folate intake and cardiovascular
disease. Several randomized clinical trials have shown that
increases in folic acid supplementation led to dramatic
decreases in homocysteine levels, which has long been linked
to cardiovascular disease [27]. More studies, especially those
that focus on the role of folic acid in primary prevention of
CV disease and studies that follow cohorts over long periods
of time, are required to address some of these issues.
5.CommentsforFurtherConsideration
Many questions remain surrounding folic acid, fortiﬁcation
policies, supplementation, and its likely or projected impact
on NTDs, public health, and a host of other diseases. Some
ofthemost pressing issues involverecent questionsabout the
role of folic acid in cancer promotion and prevention.
Because of ongoing as well as substantial eﬀorts and
collaboration of scientists, public health authorities, non-
proﬁt groups, and governmental agencies, women in many
areas of the world beneﬁt from signiﬁcant improvements
in their folic acid status through the use of folic acid
supplementation and fortiﬁcation, alone or combined. Such
eﬀorts are likely to continue, especially those with a focus
on public health strategies that target population-speciﬁc
barriers to supplement use.
This review focused on the eﬀect of folic acid intake and
supplementation (Table 1) in women, but recent evidence
also suggests that it may be of great importance in men,
not only in terms of potential cancer and/or other associated
risks, but also in terms of improving sperm quality in men
who are partners to women who are unable to conceive.
In particular, men who take supplements containing folic
acid have improved sperm counts, motility, and decreased
numbers of abnormal forms [28]. The number of such indi-
viduals is substantial, and many live in countries with few or
incomplete medical resources. In such circumstances, use of
vitamin supplements may bring cost-eﬀective opportunities
for parenthood.
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